Oxford Instruments (OXIG) Trading Update summary
Event summary combining transcript, slides, and related documents.
Trading Update summary
13 Jun, 2025Trading performance and financials
Revenue for the first half is expected to grow by around 10% at constant currency, with order intake about 3% higher than last year.
Adjusted operating profit will be slightly above last year, but group margin will be lower due to a mix shift toward Advanced Technologies.
On a reported basis, currency headwinds will result in lower adjusted operating profit and margin compared to the prior year.
The appreciation of sterling is expected to increase the currency headwind on operating profit for the full year by £1.5-2.0m from previous guidance.
Divisional highlights
Imaging & Analysis saw strong demand in materials analysis and semiconductor markets, offsetting softer healthcare & life science demand.
The division recorded a positive book-to-bill ratio in the half year.
Advanced Technologies experienced strong revenue growth in compound semiconductors and began quantum market deliveries to a key customer.
Good order book visibility continues in Advanced Technologies, supporting progress toward profitability.
Outlook and strategic initiatives
A stronger second half is anticipated, driven by execution of larger orders in Advanced Technologies and operational transformation projects.
Efficiency and cost improvements are expected from ongoing business restructuring.
Full-year performance is expected to be in line with constant currency expectations.
Latest events from Oxford Instruments
- Revenue up 9.8%, margin target above 20%, with strong growth and strategic transformation.OXIG
H2 202423 Feb 2026 - Strong order growth and capital actions support full-year profit outlook.OXIG
Q3 2026 TU15 Jan 2026 - Strong 10.4% revenue growth and robust order book drive positive full-year outlook.OXIG
H1 202515 Jan 2026 - Order recovery and cost actions set stage for stronger H2 after a challenging first half.OXIG
H1 202616 Dec 2025 - Record revenue, margin expansion, and NanoScience divestment drive strong outlook.OXIG
H2 202514 Nov 2025 - H1 order intake rose 1% OCC, but revenues fell 8% OCC; full-year outlook remains stable.OXIG
H1 2026 TU13 Oct 2025 - Strong revenue and margin growth driven by robust divisional performance and strategic execution.OXIG
Trading Update6 Jun 2025